Sponsored by: GE Healthcare

MRI: Page 142

Guerbet results benefit from Mallinckrodt deal
By AuntMinnieEurope.com staff writers
Contrast agent manufacturer Guerbet showed a sharp upturn in revenues for 2016, thanks to the contribution of sales from its acquisition of Mallinckrodt's Contrast Media and Delivery Systems (CMDS) division in 2015.
March 28, 2017
German group hones cardiac MRI for myocardial infarction
By Eric Barnes
What's the best way to distinguish acute from chronic myocardial infarction on cardiac MRI (CMR) scans? German researchers found that native T1 and T2 mapping significantly outperform conventional measurements of the T2 ratio, and they presented their results at ECR 2017.
March 27, 2017
2017 03 28 09 40 58 353 2017 03 Tahir Top 20170328164329
Analogic to launch MR-ultrasound prostate biopsy software
By AuntMinnieEurope.com staff writers
Analogic plans to launch new MR fusion prostate biopsy software for ultrasound at the European Association of Urology meeting in London.
March 23, 2017
Exact Imaging launches microultrasound/MRI device
By AuntMinnieEurope.com staff writers
Ultrasound technology developer Exact Imaging has launched a new device that combines microultrasound with MRI.
March 22, 2017
International agenda set for German national congress
By AuntMinnieEurope.com staff writers
The international program has been finalized for the 98th German Radiology Congress (Deutscher Röntgenkongress, RöKo 2017), which takes place at the Congress Center in Leipzig from 24 to 27 May.
March 21, 2017
Bracco retains faith in gadolinium-based contrast agent
By AuntMinnieEurope.com staff writers
Contrast agent manufacturer Bracco said it still believes in the risk-benefit balance of its MultiHance MR contrast agent, despite a recommendation from European regulators that it and three other linear gadolinium-based contrast agents (GBCAs) be removed from the market due to concerns over gadolinium retention in the body.
March 21, 2017
Walking a gadolinium tightrope of perception & bottom line
By Steve Holloway
The recommendation by the European Medicines Agency on 10 March that market authorization for four linear gadolinium contrast agents be suspended shocked the radiology community, but what will be the business repercussions? Analyst Stephen Holloway gives his assessment.
March 21, 2017
2017 03 21 11 45 55 23 Gadolinium2 400
Deep learning offers promise for prostate MRI reads
By Erik L. Ridley
Deep-learning software can outperform a nondeep-learning method that's been used previously in computer-aided detection software and may be able to help radiologists differentiate between prostate cancer and benign conditions on MRI, according to research presented this month at ECR 2017.
March 21, 2017
2016 10 04 11 38 34 158 Prostate 400
Mobile App Spotlight: A k-Space Odyssey
By Erik L. Ridley
AuntMinnie.com presents the next article in an ongoing series highlighting notable mobile apps in radiology. In this installment, we take a look at A k-Space Odyssey, an iOS app designed to facilitate understanding of k-space, the mathematical abstraction that connects MRI scan parameters with the clinical image.
March 20, 2017
2017 03 20 15 55 38 447 Kspace2 400
No signal intensity for pediatric patients with macrocyclic GBCA
By Wayne Forrest
German researchers have found additional evidence that the use of a macrocyclic gadolinium-based contrast agent (GBCA) for MRI scans does not increase signal intensity in the dentate nucleus. The new findings come from a study of pediatric patients published online in Radiology.
March 16, 2017
2017 03 14 17 00 39 944 Macro Gbca Mri Radbruch 400
GE requests review of European gadolinium ruling
By AuntMinnieEurope.com staff writers
GE Healthcare has requested a review of a recommendation by a European regulatory committee that recommends the suspension of the marketing authorization for one of its gadolinium-based MRI contrast agents.
March 16, 2017
Gadolinium contrast: Farewell to well-known brands
By Dr. Peter Rinck, PhD
The long wait is over for the European Medicines Agency (EMA) investigation into gadolinium contrast agents. Its noncommittal verdict punishes all manufacturers, though some are given a sweetener, but it does not shed a complimentary light upon EMA, writes the Maverinck.
March 14, 2017
2017 02 14 13 55 06 507 Maverinck Logo 400
Previous Page
Page 142 of 266
Next Page